Opthea (NASDAQ:OPT) PT Lowered to $12.00 at HC Wainwright

Opthea (NASDAQ:OPT) had its price target cut by HC Wainwright from $14.00 to $12.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Opthea’s FY2029 earnings at $0.50 EPS.

Opthea Stock Performance

OPT stock opened at $2.98 on Tuesday. The company has a 50 day moving average price of $2.35 and a 200 day moving average price of $2.93. Opthea has a fifty-two week low of $1.60 and a fifty-two week high of $4.40.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.